PD-L1 expression and prognosis in definitive radiotherapy patients with neuroendocrine cervical carcinoma

作者：Huiling Li, Xiuhua Li, Meichun Yang, Huiyan Su, Jianqiu Zhang, Chunmiao Hu, Yingming Sun, Dan Hu, Li Chen · 发表于：Journal of Clinical and Translational Research · 年份：2023 · DOI：10.18053/jctres.09.202304.23-00067 · 被引用次数：2 · 研究领域：Neuroendocrine Tumor Research Advances、Endometrial and Cervical Cancer Treatments、Lung Cancer Research Studies

Background: Neuroendocrine carcinoma of the cervix (NECC) is more prone to lymphatic infiltration, lymph node involvement, local recurrence, and distant metastasis. Using CCRT with or without adjuvant chemotherapy as the standard treatment for locally advanced NECCs and CCRT for patients with early lesions confined to the cervix. However, the prognosis of NECC patients treated with definitive radiotherapy (RT) is unknown. Immune checkpoint inhibitors are a promising therapeutic strategy for locally advanced cervical cancer. Some reports suggest that the expression of PD-L1 in solid tumors correlates with prognosis. Aim: This study investigates prognostic factors for survival in patients with neuroendocrine cervical carcinoma (NECC) treated with definitive radiotherapy (RT) and the relationship between PD-L1 expression and prognosis in these patients. Methods: This retrospective study included 66 patients with histologically confirmed NECC who received RT with or without chemotherapy. From January 2015 to December 2020, patients received routine extended-field irradiation (EFI), and PD-L1 expression was assessed by immunohistochemistry. The most commonly used chemotherapy agents were etoposide-platinum and paclitaxel-platinum. Results: PD-L1 expression was positive in 17 of 45 (37.8%) patients. There were 52 cases of pure NECC and 14 cases of mixed carcinoma. Sixty stage IB-III patients received definitive RT. The 3- and 5-year progression-f...